Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2023-05-11 Regulatory Filings
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes an amendment to a material definitive agreement related to convertible notes and warrants, and an announcement of a patent award. There are no financial statements or detailed financial performance data presented, nor is this an earnings release or annual/interim report. The document primarily reports on a material contract amendment and other significant corporate events. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2023-05-11 English
Board/Management Information 2023
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 1, 2023. The key content is an announcement regarding the award of an annual bonus to the CEO, which is a change related to compensatory arrangements of a senior officer. There is no financial statement or detailed financial data presented, nor is it an earnings release or annual report. The focus is on management compensation and changes related to officers. This fits the category of Board/Management Information (MANG), which includes announcements of changes in senior management or related compensatory arrangements. The document length is 4005 characters, which is short but contains substantive information about management compensation, not just a notice or certification. Therefore, the appropriate classification is MANG with high confidence.
2023-05-03 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Shuttle Pharmaceuticals Holdings, Inc. It reports on several events including entry into a material definitive agreement, change in the company's certifying accountant, and furnishing of an updated investor presentation. The document includes detailed descriptions of these events and references exhibits such as agreements and letters from accountants. It does not contain financial statements or detailed financial performance data itself, but rather reports on corporate events and changes. The presence of a change in auditor and material agreements is typical content for an 8-K filing, which is a current report for significant corporate events. This type of filing is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Earnings Release, or Management Reports.
2023-03-22 English
Annual Report 2022
Annual Report FY 2022
2023-03-15 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or agreements that are material to the company. The text describes the entry into a material definitive agreement (a service agreement) and includes a press release about this event. There are no financial statements or detailed financial data presented, and the document is not an annual or quarterly report. It is not a certification or a proxy statement. The document is a regulatory announcement of a material event, fitting the category of Regulatory Filings (RNS). The length is under 5,000 characters, and it is a standalone announcement rather than a full report.
2023-03-09 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-03-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.